The viscosupplementation market is estimated to be valued at USD 4.15 Bn in 2025 and is expected to reach USD 7.11 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8% from 2025 to 2032.
To learn more about this report, Download Free Sample
The global viscosupplementation market is witnessing steady growth, led by the growing incidence of osteoarthritis and demand for less invasive, pain-relieving treatments. The aging population, especially in mature and emerging economies, continues to propel demand for intra-articular hyaluronic acid injections that improve joint mobility, alleviate pain, and postpone joint replacement surgery. Growing uses in outpatient orthopedic treatment and sports medicine are also driving the market momentum.
|
Current Events |
Description and its impact |
|
Push Towards Green Hyaluronic Acid Production
|
|
|
Integration of AI Diagnostics and Smart Injection Systems
|
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
To learn more about this report, Download Free Sample
Since the global population is ageing greatly, elderly individuals with a risk of mobility issues and joint disorders are growing at a tremendous rate. Osteoarthritis is one of the leading causes of disability in the elderly population globally. It most often affects the hands, hips, and knees and can render even simple movements painfully difficult. Since people are living longer as a result of advancements in healthcare and nutrition, osteoarthritis has reached epidemic proportion.
Increasing numbers of older adults are driving the need for effective osteoarthritis treatment and pain relief. Viscosupplementation procedures cushion and lubricate osteoarthritic joints, facilitating movement while minimizing pain. They enable most older patients to forgo joint replacement surgery or other surgery, enhancing their quality of life.
International Internet and support group spread of health information has increased awareness about a range of non-surgical osteoarthritis options. Conservative treatment options to joint replacement, at least in the earlier stages of the disease, are increasingly being selected by patients. Viscosupplementation procedures are particularly appealing here since they are non-surgical and entail mere local injections to enrich joint fluid viscosity.
Unlike the sometimes-exuberant alternative of joint replacement, viscosupplementation permits patients to avoid complicated surgery and extended rehabilitation. It preserves the natural joint and improves mobility without extensive downtime or the risks of surgery.
With rising geriatric populations worldwide, the prevalence of osteoarthritis is increasing rapidly. This growing patient pool suffering from joint pain indicates higher demand. Furthermore, ongoing research into newer viscosupplements promises treatments that are longer-lasting or require fewer injections. Expanded health coverage through insurance plans could help boost the market by facilitating access.
The dosage segment includes single injection, three injection, and five injections. Three injection is anticipated to hold 46.3% of the market share in 2025. Completing a full treatment course in just three visits increases compliance rates compared to longer five injection regimens. Busy patients appreciate that Three Injection shortens disruption to their daily routine.
Healthcare providers also favor Three Injection, as three visits reduces the burden on resources versus single alternatives that may require additional follow up appointments due to incomplete relief of symptoms. The consistent dosing schedule of Three Injection further aids treatment adherence. Receiving regular injections on the same cadence helps patients establish a routine and stick to their care plan.
In contrast, options with varied intervals like single or five injections can confuse patients and compromise how diligently they follow prescription instructions. Overall, Three Injection strikes the right balance for most osteoarthritis sufferers seeking prompt symptom relief without excessive disruption to work and personal obligations.
The arthritis type segment includes osteoarthritis and rheumatoid arthritis. Osteoarthritis contributes the highest share of the viscosupplementation market and is projected to hold 68.3% of the market share in 2025. Osteoarthritis accounts for over 60% of all arthritis cases and directly affects 27 million Americans, with many more affected indirectly as caregivers. The sheer scale of the eligible patient pool makes it the dominant market segment.
Additionally, the degenerative nature of osteoarthritis often limits the effectiveness of alternatives like medication management alone. Viscosupplementation offers a minimally invasive solution preferred by both patients and providers over joint replacement in earlier disease stages.
The end user segment includes hospitals, specialty clinics, ambulatory surgical centers, and others. Hospitals contribute the highest share of the viscosupplementation market and is projected to hold 48.7% of the market share in 2025. As arthritis disproportionately affects the elderly, many patients rely on hospitals for more involved treatment plans that integrate viscosupplementation alongside comprehensive arthritis management.
In contrast to stand-alone clinics, hospitals offer a full spectrum of related specialists under one roof including rheumatologists, orthopedic surgeons, and physical therapists. Hospitals also boast advanced imaging technology that aids accurate assessment and monitoring of treatment progress.
Dedicated operating rooms allow hospitals to efficiently perform procedures for patients who require injections combined with arthrocentesis or joint lavage for improved distribution of supplements to targeted areas. Their round-the-clock services further accommodate patients with limited mobility or availability.
To learn more about this report, Download Free Sample
North America has established itself as the dominant regional market for viscosupplementation and is expected to hold 48.3% of the market share in 2025. With a strong presence of leading medical device manufacturers and favorable reimbursement policies for knee osteoarthritis treatments, the U.S. accounts for the major share in the regional market.
The growing adoption of minimally invasive procedures and rising obesity rates that increase the risk of osteoarthritis have further augmented demand over the years. Additionally, well-established distribution channels ensure easy accessibility to products across the region.
The viscosupplementation market in Asia Pacific has emerged as the fastest growing regional market globally. Countries like China, India, Japan, and South Korea are witnessing substantial rise in knee osteoarthritis cases driven by growing geriatric population and increasing lifestyle disease prevalence. This has boosted the uptake of viscosupplementation as an effective non-surgical treatment option.
The market is also gaining from economic development across emerging nations, growing medical tourism, and improving access to healthcare facilities. Local manufacturers are augmenting their presence to cater to the rising needs. For instance, some Chinese companies have indigenously developed cost-effective viscosupplements to tap into the domestic demand.
The United States dominates the world viscosupplementation market due to a high population with aging, high incidence of osteoarthritis, and well-developed healthcare infrastructure. The nation is also characterized by early acceptance of new treatments and established market presence of major players such as Zimmer Biomet and Sanofi.
Germany is the largest European market for viscosupplementation. The country's emphasis on orthopedic treatment, along with the presence of a high elderly population and government encouragement for minimally invasive surgeries, all add to the market growth.
Japan is a priority market within the Asia-Pacific region because of its rapidly aging population and high prevalence of knee osteoarthritis. The nation also possesses a highly developed healthcare system as well as increasing awareness of non-surgical care such as viscosupplementation.
China's viscosupplementation market is growing speedily, driven by its large population, rising incidence of osteoarthritis, and growing healthcare expenditure. Urbanization and enhanced access to healthcare services are also driving demand for non-surgical joint therapies.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 4.15 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 8% | 2032 Value Projection: | USD 7.11 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Anika Therapeutics Inc., Seikagaku Corporation, Ferring Pharmaceuticals, Bioventus, Fidia Farmaceutici S.P.A., Mylan N.V., Sanofi S.A., OrthogenRx, Teva Pharmaceutical Industries Ltd, Johnson & Johnson., F. Hoffmann-La Roche AG, Zimmer Biomet, Aptissen, Wellchem Pharmaceuticals Pte Ltd., Juniper Biologics, and Ono Pharmaceutical Co., Ltd |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
About Author
Vipul Patil is a dynamic management consultant with 6 years of dedicated experience in the pharmaceutical industry. Known for his analytical acumen and strategic insight, Vipul has successfully partnered with pharmaceutical companies to enhance operational efficiency, cross broader expansion, and navigate the complexities of distribution in markets with high revenue potential.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
Schedule a meeting with report Author
